Health
Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant – News-Medical.Net
Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory…
Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The new B.1.1.7 variant, which has higher transmission potential than previous SARS-CoV-2 strains, recently emerged in the UK, South Africa and Brazil and has now been identified in 50 countries.
The emergence of B.1.1.7 has triggered…
-
General21 hours agoWondering about winter | The Spectator Australia
-
Noosa News20 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
General20 hours agoNo ‘band-aid solution’: sweating coal risky business
-
General20 hours agoParents of Heidi, 3, remember ‘beautiful’ daughter killed in Ocean Grove crash